OR WAIT 15 SECS
Fremont, CA - July 16, 2009 - Velos, Inc., the trusted leader in clinical research management systems, announced today the availability of new system capabilities to ensure that the cancer center community can fulfill new registration requirements for the U.S. National Cancer Institute (NCI) Clinical Trials Reporting Program, (CTRP). Velos has proactively developed these capabilities and functions in its Velos eResearch platform to ease and streamline registration of interventional trials. The content, based on specifications published for the CTRP, delivers capabilities for customers to create outputs that can be uploaded to the NCI in specified formats.
“Our priority is to support the NCI and, at the same time, to help cancer centers work successfully with these new requirements,” said Priti Sahai, M.D., Velos Vice President for Product Development. “The abiding mission at Velos has always been to promote the NCI and its objectives. We’re committed to facilitating their efforts to gain needed, up-to-date information. We have a shared goal to optimize investment in cancer research.”
Recently, the NCI formalized the establishment of a comprehensive database that would contain regularly updated information about all NCI-funded clinical trials. The NCI initiated a phased launch of the CTRP in January 2009, with five “Pilot Sites” posting new studies. Pilot sites actively participated in the development process of the program itself. By July, a group of “Early Adopter” sites were identified by the NCI and these sites have begun the process of posting new interventional studies to the NCI database. Changes to existing trials will also be posted and it is expected that by the end of 2009, the process will be well underway with all NCI grantees posting proscribed information on all interventional trials. Registration of observational, ancillary and correlative studies will begin in 2010.
“We at Velos are consistently watchful and alert to all indicators from the NCI regarding new programs to which our cancer center community will need to respond,” continued Dr. Sahai. “These registration requirements are important to the NCI and to the industry as a whole because they are an essential, information-gathering initiative. Through this program, the NCI can carry out a prioritization process to more effectively focus resources on trials judged most likely to facilitate advances in treatment. However, they are not without complexity, and they impose a significant new workload on the cancer care and research community. Our effort with this new release of capabilities is to minimize effort and maximize automation in support of the new trial reporting requirements.”
CTRP has published specifications and the new Velos eResearch software, with built-in compatibility to these standards, has been released to sites. Customers who would otherwise be burdened by multiple manual, software, and email reporting processes now have a streamlined, single system with one data source, resulting in multiple CTRP-ready outputs. Despite the complexity of the new reporting requirements, all the new content was prepared by Velos teams, using flexible toolkits in the system, with no changes to core code, and no system downtime for customers. Velos customers who have been designated “Early Adopters” of the CTRP are now completing the required registrations and data transfers using the new Velos eResearch functionality.
About the Clinical Trials Reporting Program at the NCI
NCI’s new Clinical Trials Reporting Program fulfills a recommendation made by the NCI Clinical Trials Working Group to the National Cancer Advisory Board. The purpose of the program is to establish a comprehensive database containing regularly updated information on all NCI-funded interventional clinical trials. Grantees will enter specific information about each clinical trial into the database. NCI will use this information to coordinate research efforts to optimize our nation’s investment in cancer research. NCI initiated a phased launch of CTRP, which started in 2009 with a focus on registering interventional trials only. For more information, visit http://www.cancer.gov/clinicaltrials/ctrp.
Velos is the trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S. The company serves 21 Top 25* U.S. medical centers. Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. The system fundamentally improves the way data is collected, organized and shared. A pure Internet technology platform, Velos eResearch harnesses advanced powers of the Internet to enable research sites, sponsors, and patients to participate in a secure, integrated system platform. System users are freed of redundant data entry and related time delays associated with most clinical research today. With emphasis on workflow, Velos integrates the clinical, administrative and financial information needs of research management. Velos eTools, a companion product to Velos eResearch, empowers customers by giving them ownership and access to functions such as system configuration, data migrations, custom reporting and third party data submissions. Velos is privately held with headquarters in Fremont, California. For more information, visit www.velos.com.
# # #
This press release may contain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements.
*U.S. News & World Report, Best Hospitals Survey